JAK2 and leukemia: All Dox-treated (Jak2-off) recipient mice harboring Jak2 knockdown-persistent cells exhibited a delay in leukemia progression and conferred a significant survival benefit over the untreated (Jak2-on) cohort (Fig. 4B).